Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Clinical Epidemiology and the Impact of Comorbidity on Treatment and Outcome

  • Chapter
  • First Online:
Management of Lung Cancer in Older People

  • 1119 Accesses

Abstract

In the beginning of the twentieth century lung cancer was a very rare disease, but rates have increased so dramatically that lung cancer can be considered one of the major epidemics of the twentieth century. Currently, lung cancer is still number one cause of death among cancer deaths. Over fifty percent of all newly diagnosed lung cancer patients are aged over 65 years at the time of lung cancer diagnosis, and about 30% are aged over 70. Since lung cancer is a disease that mainly occurs in elderly and smoking is the most important risk factor, many patients have (smoking-related) comorbidity at the time of lung cancer diagnosis. This may complicate the management of lung cancer in elderly patients. Elderly receive standard treatment less often, although standard treatment has a positive effect on prognosis of lung cancer, even after adjustment for differences in age and comorbidity. However, complications of treatment among elderly patients are very common, despite a strict selection of the fittest elderly for standard treatment. In elderly, the impact of toxicities on quality-of-life may be just as important as the prolongation of life expectancy. A proper selection of patients fit enough for surgery, chemotherapy and/or radiotherapy is therefore important and there is an urgent need for predictive models for treatment tolerance that can be easily used in everyday clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Levi F, Lucchini F, Negri E, et al. Cancer mortality in Europe, 1995–1999, and an overview of trends since 1960. Int J Cancer. 2004;110:155–69.

    Article  PubMed  CAS  Google Scholar 

  2. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer. 2003;41:245–58.

    Article  PubMed  Google Scholar 

  3. Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries. Eur J Cancer. 2004;40:96–125.

    Article  PubMed  CAS  Google Scholar 

  4. Devesa SS, Silverman DT, Young JL, et al. Cancer incidence and mortality trends among whites in the United States, 1947–84. J Natl Cancer Inst. 1987;79:701–70.

    PubMed  CAS  Google Scholar 

  5. Horm JW, Kessler LG. Falling rates of lung cancer in men in the United States. Lancet. 1986;1:425–6.

    Article  PubMed  CAS  Google Scholar 

  6. Janssen-Heijnen ML, Nab HW, van Reek J, et al. Striking changes in smoking behaviour and lung cancer incidence by histological type in south-east Netherlands, 1960–1991. Eur J Cancer. 1995;31A:949–52.

    Article  PubMed  CAS  Google Scholar 

  7. McCredie M, Coates MS, Ford JM. The changing incidence of cancer in adults in New South Wales. Int J Cancer. 1988;42:667–71.

    Article  PubMed  CAS  Google Scholar 

  8. O’Lorcain P, Comber H. Lung cancer mortality predictions for Ireland 2001–2015 and current trends in North Western Europe. Lung Cancer. 2004;46:157–63.

    Article  PubMed  Google Scholar 

  9. Skuladottir H, Olsen JH, Hirsch FR. Incidence of lung cancer in Denmark: historical and actual status. Lung Cancer. 2000;27:107–18.

    Article  PubMed  CAS  Google Scholar 

  10. Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer. 1996;77:2464–70.

    Article  PubMed  CAS  Google Scholar 

  11. Tyczynski JE, Bray F, Aareleid T, et al. Lung cancer mortality patterns in selected Central, Eastern and Southern European countries. Int J Cancer. 2004;109:598–610.

    Article  PubMed  CAS  Google Scholar 

  12. Russo A, Crosignani P, Franceschi S, Berrino F. Changes in lung cancer histological types in Varese Cancer Registry, Italy 1976–1992. Eur J Cancer. 1997;33:1643–7.

    Article  PubMed  CAS  Google Scholar 

  13. Boffetta P, La Vecchia C, Levi F, Lucchini F. Mortality patterns and trends for lung cancer and other tobacco-related cancers in the Americas, 1955–1989. Int J Epidemiol. 1993;22:377–84.

    Article  PubMed  CAS  Google Scholar 

  14. La Vecchia C, Lucchini F, Negri E, et al. Trends in cancer mortality in the Americas, 1955–1989. Eur J Cancer. 1993;29A:431–70.

    Article  PubMed  Google Scholar 

  15. Morita T. A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J Cancer Res. 2002;93:15–23.

    Article  PubMed  CAS  Google Scholar 

  16. Karim-Kos HE, Janssen-Heijnen ML, van Iersel CA, et al. The beginning of the end of the lung cancer epidemic in Dutch women? Int J Cancer. 2008;123:1472–5.

    Article  PubMed  CAS  Google Scholar 

  17. Chiu YL, Yu IT, Wong TW. Time trends of female lung cancer in Hong Kong: age, period and birth cohort analysis. Int J Cancer. 2004;111:424–30.

    Article  PubMed  CAS  Google Scholar 

  18. Havlik RJ, Yancik R, Long S, et al. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer. 1994;74:2101–6.

    Article  PubMed  CAS  Google Scholar 

  19. Janssen-Heijnen ML, Coebergh JW, Klinkhamer PJ, et al. Is there a common etiology for the rising incidence of and decreasing survival with adenocarcinoma of the lung? Epidemiology. 2001;12:256–8.

    Article  PubMed  CAS  Google Scholar 

  20. Levi F, Franceschi S, La Vecchia C, et al. Lung carcinoma trends by histologic type in Vaud and Neuchatel, Switzerland, 1974–1994. Cancer. 1997;79:906–14.

    Article  PubMed  CAS  Google Scholar 

  21. Thun MJ, Lally CA, Flannery JT, et al. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst. 1997;89:1580–6.

    Article  PubMed  CAS  Google Scholar 

  22. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ. 1994;309:901–11.

    Article  PubMed  CAS  Google Scholar 

  23. Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst. 1984;73:383–9.

    PubMed  CAS  Google Scholar 

  24. Harris JE, Thun MJ, Mondul AM, Calle EE. Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982–8. BMJ. 2004;328:72.

    Article  PubMed  Google Scholar 

  25. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004;45 Suppl 2:S3–9.

    Article  PubMed  Google Scholar 

  26. de Waard F, Kemmeren JM, van Ginkel LA, Stolker AA. Urinary cotinine and lung cancer risk in a female cohort. Br J Cancer. 1995;72:784–7.

    Article  PubMed  Google Scholar 

  27. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 1996;274:430–2.

    Article  PubMed  CAS  Google Scholar 

  28. Engeland A, Haldorsen T, Andersen A, Tretli S. The impact of smoking habits on lung cancer risk: 28 years’ observation of 26,000 Norwegian men and women. Cancer Causes Control. 1996;7:366–76.

    Article  PubMed  CAS  Google Scholar 

  29. Morabia A, Wynder EL. Cigarette smoking and lung cancer cell types. Cancer. 1991;68:2074–8.

    Article  PubMed  CAS  Google Scholar 

  30. Pezzotto SM, Mahuad R, Bay ML, et al. Variation in smoking-related lung cancer risk factors by cell type among men in Argentina: a case–control study. Cancer Causes Control. 1993;4:231–7.

    PubMed  CAS  Google Scholar 

  31. Siemiatycki J, Krewski D, Franco E, Kaiserman M. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case–control study. Int J Epidemiol. 1995;24:504–14.

    Article  PubMed  CAS  Google Scholar 

  32. Simonato L, Agudo A, Ahrens W, et al. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity. Int J Cancer. 2001;91:876–87.

    Article  PubMed  CAS  Google Scholar 

  33. Higgins IT, Wynder EL. Reduction in risk of lung cancer among ex-smokers with particular reference to histologic type. Cancer. 1988;62:2397–401.

    Article  PubMed  CAS  Google Scholar 

  34. Makitaro R, Paakko P, Huhti E, et al. An epidemiological study of lung cancer: history and histological types in a general population in northern Finland. Eur Respir J. 1999;13:436–40.

    Article  PubMed  CAS  Google Scholar 

  35. Dorant E, van den Brandt PA, Goldbohm RA. A prospective cohort study on Allium vegetable consumption, garlic supplement use, and the risk of lung carcinoma in The Netherlands. Cancer Res. 1994;54:6148–53.

    PubMed  CAS  Google Scholar 

  36. Margetts BM, Jackson AA. Interactions between people’s diet and their smoking habits: the dietary and nutritional survey of British adults. BMJ. 1993;307:1381–4.

    Article  PubMed  CAS  Google Scholar 

  37. Scali J, Astre C, Segala C, Gerber M. Relationship of serum cholesterol, dietary and plasma beta-carotene with lung cancer in male smokers. Eur J Cancer Prev. 1995;4:169–74.

    Article  PubMed  CAS  Google Scholar 

  38. Serdula MK, Byers T, Mokdad AH, et al. The association between fruit and vegetable intake and chronic disease risk factors. Epidemiology. 1996;7:161–5.

    Article  PubMed  CAS  Google Scholar 

  39. Ziegler RG, Colavito EA, Hartge P, et al. Importance of alpha-carotene, beta-carotene, and other phytochemicals in the etiology of lung cancer. J Natl Cancer Inst. 1996;88:612–5.

    Article  PubMed  CAS  Google Scholar 

  40. Lubin JH, Boice Jr JD. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J Natl Cancer Inst. 1997;89:49–57.

    Article  PubMed  CAS  Google Scholar 

  41. Alavanja MC, Brownson RC, Berger E, et al. Avian exposure and risk of lung cancer in women in Missouri: population based case–control study. BMJ. 1996;313:1233–5.

    Article  PubMed  CAS  Google Scholar 

  42. Gardiner AJ, Forey BA, Lee PN. Avian exposure and bronchogenic carcinoma. BMJ. 1992;305:989–92.

    Article  PubMed  CAS  Google Scholar 

  43. Holst PA, Kromhout D, Brand R. For debate: pet birds as an independent risk factor for lung cancer. BMJ. 1988;297:1319–21.

    Article  PubMed  CAS  Google Scholar 

  44. Kohlmeier L, Arminger G, Bartolomeycik S, et al. Pet birds as an independent risk factor for lung cancer: case–control study. BMJ. 1992;305:986–9.

    Article  PubMed  CAS  Google Scholar 

  45. Modigh C, Axelsson G, Alavanja M, et al. Pet birds and risk of lung cancer in Sweden: a case–control study. BMJ. 1996;313:1236–8.

    Article  PubMed  CAS  Google Scholar 

  46. Littman AJ, Thornquist MD, White E, et al. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control. 2004;15:819–27.

    Article  PubMed  Google Scholar 

  47. Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55:231–40.

    Article  PubMed  Google Scholar 

  48. Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax. 2004;59:602–7.

    Article  PubMed  CAS  Google Scholar 

  49. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.

    Article  PubMed  CAS  Google Scholar 

  50. Read WL, Tierney RM, Page NC, et al. Differential prognostic impact of comorbidity. J Clin Oncol. 2004;22:3099–103.

    Article  PubMed  Google Scholar 

  51. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–7.

    PubMed  CAS  Google Scholar 

  52. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005;10:198–204.

    Article  PubMed  Google Scholar 

  53. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.

    Article  PubMed  Google Scholar 

  54. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23:3112–24.

    Article  PubMed  Google Scholar 

  55. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–300.

    Article  PubMed  Google Scholar 

  56. Bremnes RM, Andersen K, Wist EA. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer. 1995;31A:1955–9.

    Article  PubMed  CAS  Google Scholar 

  57. Rose JH, O’Toole EE, Dawson NV, et al. Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer. J Clin Oncol. 2004;22:4907–17.

    Article  PubMed  Google Scholar 

  58. Cykert S, Dilworth-Anderson P, Monroe MH, et al. Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA. 2010;303:2368–76.

    Article  PubMed  CAS  Google Scholar 

  59. Damhuis RA, Schutte PR. Resection rates and postoperative mortality in 7,899 patients with lung cancer. Eur Respir J. 1996;9:7–10.

    Article  PubMed  CAS  Google Scholar 

  60. Finlayson EV, Birkmeyer JD. Operative mortality with elective surgery in older adults. Eff Clin Pract. 2001;4:172–7.

    PubMed  CAS  Google Scholar 

  61. Janssen-Heijnen ML, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007;43:2179–93.

    Article  PubMed  Google Scholar 

  62. Okami J, Higashiyama M, Asamura H, et al. Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications. J Thorac Oncol. 2009;4:1247–53.

    Article  PubMed  Google Scholar 

  63. Veen EJ, Janssen-Heijnen ML, Ritchie ED, et al. Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome. Interact Cardiovasc Thorac Surg. 2009;9:260–4.

    Article  PubMed  Google Scholar 

  64. Dominguez-Ventura A, Allen MS, Cassivi SD, et al. Lung cancer in octogenarians: factors affecting morbidity and mortality after pulmonary resection. Ann Thorac Surg. 2006;82:1175–9.

    Article  PubMed  Google Scholar 

  65. Dyszkiewicz W, Pawlak K, Gasiorowski L. Early post-pneumonectomy complications in the elderly. Eur J Cardiothorac Surg. 2000;17:246–50.

    Article  PubMed  CAS  Google Scholar 

  66. Landreneau RJ, Sugarbaker DJ, Mack MJ, et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997;113:691–8; discussion 698–700.

    Article  PubMed  CAS  Google Scholar 

  67. Van der Drift MA, Karim-Kos HE, Siesling S, et al. Progress in standard of care therapy and modest survival benefits in the treatment of NSCLC patients in the Netherlands in the last 20 years. J Thorac Oncol. 2012;7:291–8.

    Article  PubMed  Google Scholar 

  68. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27:3290–6.

    Article  PubMed  Google Scholar 

  69. Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.

    Article  PubMed  Google Scholar 

  70. Palma D, Visser O, Lagerwaard FJ, et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28:5153–9.

    Article  PubMed  Google Scholar 

  71. De Ruysscher D, Faivre-Finn C, Nestle U, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2011;28:5301–10.

    Article  Google Scholar 

  72. Haasbeek CJ, Lagerwaard FJ, Antonisse ME, et al. Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer. 2011;116:406–14.

    Article  Google Scholar 

  73. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.

    Article  PubMed  Google Scholar 

  74. Chrischilles EA, Pendergast JF, Kahn KL, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 2011;28:620–7.

    Article  Google Scholar 

  75. Pallis AG, Karampeazis A, Vamvakas L, et al. Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group. Ann Oncol. 2011;22:2448–55.

    Article  PubMed  CAS  Google Scholar 

  76. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003;21:3201–6.

    Article  PubMed  CAS  Google Scholar 

  77. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2011;28:2191–7.

    Article  Google Scholar 

  78. Gronberg BH, Sundstrom S, Kaasa S, et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2011;46:2225–34.

    Article  CAS  Google Scholar 

  79. Ngeow J, Leong SS, Gao F, et al. Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status. Crit Rev Oncol Hematol. 2011;76:53–60.

    Article  Google Scholar 

  80. de Rijke JM, Schouten LJ, ten Velde GP, et al. Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer. 2004;46:233–45.

    Article  PubMed  Google Scholar 

  81. Wanders R, Steevens J, Botterweck A, et al. Treatment with curative intent of stage III non-small cell lung cancer patients of 75years: a prospective population-based study. Eur J Cancer. 2011;47:2691–7.

    Article  PubMed  Google Scholar 

  82. Gridelli C, Perrone F, Gallo C, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer. 1997;33:392–7.

    Article  PubMed  CAS  Google Scholar 

  83. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol. 2005;23:3125–37.

    Article  PubMed  CAS  Google Scholar 

  84. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330–53.

    Article  PubMed  Google Scholar 

  85. Gridelli C, Ardizzoni A, Douillard JY, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 2010;68:319–31.

    Article  PubMed  Google Scholar 

  86. Biesma B, Wymenga AN, Vincent A, et al. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol. 2011;22:1520–7.

    Article  PubMed  CAS  Google Scholar 

  87. Gridelli C, Maione P, Illiano A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol. 2007;25:4663–9.

    Article  PubMed  CAS  Google Scholar 

  88. Quoix E, Westeel V, Zalcman G, Milleron B. Chemotherapy in elderly patients with advanced non-small cell lung cancer. Lung Cancer. 2011;74:364–8.

    Article  PubMed  Google Scholar 

  89. Choi NC, Carey RW, Kaufman SD, et al. Small cell carcinoma of the lung. A progress report of 15 years’ experience. Cancer. 1987;59:6–14.

    Article  PubMed  CAS  Google Scholar 

  90. Janssen-Heijnen ML, Schipper RM, Klinkhamer PJ, et al. Improvement and plateau in survival of small-cell lung cancer since 1975: a population-based study. Ann Oncol. 1998;9:543–7.

    Article  PubMed  CAS  Google Scholar 

  91. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years–an analysis of 1,714 consecutive patients. J Clin Oncol. 1995;13:1215–20.

    PubMed  CAS  Google Scholar 

  92. Skarin AT. Analysis of long-term survivors with small-cell lung cancer. Chest. 1993;103:440S–4.

    Article  PubMed  CAS  Google Scholar 

  93. Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer. 1990;61:584–9.

    Article  PubMed  CAS  Google Scholar 

  94. Amarasena IU, Walters JA, Wood-Baker R, Fong K. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev. 2008; (4):CD006849.

    Google Scholar 

  95. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378:1741–55.

    Article  PubMed  Google Scholar 

  96. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–84.

    Article  PubMed  CAS  Google Scholar 

  97. Arriagada R, Le Chevalier T, Riviere A, et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol. 2002;13:748–54.

    Article  PubMed  CAS  Google Scholar 

  98. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.

    Article  PubMed  CAS  Google Scholar 

  99. Deppermann KM. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer. 2001;33 Suppl 1:S115–20.

    Article  PubMed  Google Scholar 

  100. Janssen-Heijnen ML, Lemmens VE, van den Borne BE, et al. Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: a population-based study in the Netherlands. Crit Rev Oncol Hematol. 2007;62:172–8.

    Article  PubMed  CAS  Google Scholar 

  101. Jara C, Gomez-Aldaravi JL, Tirado R, et al. Small-cell lung cancer in the elderly–is age of patient a relevant factor? Acta Oncol. 1999;38:781–6.

    Article  PubMed  CAS  Google Scholar 

  102. Ludbrook JJ, Truong PT, MacNeil MV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys. 2003;55:1321–30.

    Article  PubMed  Google Scholar 

  103. Weinmann M, Jeremic B, Bamberg M, Bokemeyer C. Treatment of lung cancer in elderly part II: small cell lung cancer. Lung Cancer. 2003;40:1–16.

    Article  PubMed  Google Scholar 

  104. Lally BE, Geiger AM, Urbanic JJ, et al. Trends in the outcomes for patients with limited stage small cell lung cancer: an analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer. 2009;64:226–31.

    Article  PubMed  Google Scholar 

  105. Janssen-Heijnen ML, Maas HA, van de Schans SA, et al. Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it? Ann Oncol. 2010;22:821–6.

    Article  PubMed  Google Scholar 

  106. Kim HG, Lee GW, Kang JH, et al. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or = 65 years) with extensive-disease small-cell lung cancer. Lung Cancer. 2008;61:220–6.

    Article  PubMed  Google Scholar 

  107. Siu LL, Shepherd FA, Murray N, et al. Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol. 1996;14:821–8.

    PubMed  CAS  Google Scholar 

  108. Janssen-Heijnen ML, Maas HA, Siesling S, et al. Treatment and survival of patients with small-cell lung cancer: small steps forward, but not for patients >80. Ann Oncol. 2011;23:954–60.

    Article  PubMed  Google Scholar 

  109. Janssen-Heijnen ML, Karim-Kos HE, van der Drift MA, et al. Modest improvements of survival for patients with small cell lung cancer aged 45 to 59 years only, diagnosed in the Netherlands, 1989 to 2008. J Thorac Oncol. 2011;7:227–32.

    Article  Google Scholar 

  110. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12:627–42.

    PubMed  CAS  Google Scholar 

  111. Capocaccia R, Negri E, La Vecchia C, Decarli A. Trends in lung cancer mortality in three broad Italian geographical areas between 1969 and 1987. Eur J Cancer. 1993;29A:1288–93.

    Article  PubMed  CAS  Google Scholar 

  112. Quaglia A, Tavilla A, Shack L, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur J Cancer. 2009;45:1006–16.

    Article  PubMed  Google Scholar 

  113. Foucher P, Coudert B, Arveux P, et al. Age and prognosis of non-small cell lung cancer. Usefulness of a relative survival model. Eur J Cancer. 1993;29A:1809–13.

    Article  PubMed  CAS  Google Scholar 

  114. Grosclaude P, Galat JP, Mace-Lesech J, et al. Differences in treatment and survival rates of non-small-cell lung cancer in three regions of France. Br J Cancer. 1995;72:1278–82.

    Article  PubMed  CAS  Google Scholar 

  115. Janssen-Heijnen ML, Gatta G, Forman D, et al. Variation in survival of patients with lung ­cancer in Europe, 1985–1989. EUROCARE Working Group. Eur J Cancer. 1998;34:2191–6.

    Article  PubMed  CAS  Google Scholar 

  116. Pastorino U, Berrino F, Valente M, et al. Incident lung cancer survival. Long-term follow-up of a population-based study in Italy. Tumori. 1990;76:199–204.

    PubMed  CAS  Google Scholar 

  117. Janssen-Heijnen ML, Schipper RM, Klinkhamer PJ, et al. Divergent changes in survival for histological types of non-small-cell lung cancer in the southeastern area of The Netherlands since 1975. Br J Cancer. 1998;77:2053–7.

    Article  PubMed  CAS  Google Scholar 

  118. Sant M, Gatta G, Capocaccia R, et al. Survival for lung cancer in northern Italy. Cancer Causes Control. 1992;3:223–30.

    Article  PubMed  CAS  Google Scholar 

  119. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75:191–202.

    Article  PubMed  CAS  Google Scholar 

  120. Connolly CK, Jones WG, Thorogood J, et al. Investigation, treatment and prognosis of bronchial carcinoma in the Yorkshire Region of England 1976–1983. Br J Cancer. 1990;61:579–83.

    Article  PubMed  CAS  Google Scholar 

  121. Watkin SW, Hayhurst GK, Green JA. Time trends in the outcome of lung cancer management: a study of 9,090 cases diagnosed in the Mersey Region, 1974–86. Br J Cancer. 1990;61:590–6.

    Article  PubMed  CAS  Google Scholar 

  122. Davis S, Wright PW, Schulman SF, et al. Long-term survival in small-cell carcinoma of the lung: a population experience. J Clin Oncol. 1985;3:80–91.

    PubMed  CAS  Google Scholar 

  123. Findlay MP, Griffin AM, Raghavan D, et al. Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means? Eur J Cancer. 1991;27:1597–601.

    Article  PubMed  CAS  Google Scholar 

  124. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986;46:4189–94.

    PubMed  CAS  Google Scholar 

  125. van der Gaast A, Postmus PE, Burghouts J, et al. Long term survival of small cell lung cancer patients after chemotherapy. Br J Cancer. 1993;67:822–4.

    Article  PubMed  Google Scholar 

  126. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol. 2004;22:3261–8.

    Article  PubMed  Google Scholar 

  127. Janssen-Heijnen ML, Van de Schans SA. Epidemiology of geriatric oncology. In: ­Pérez-Manga G, Repetto L, editors. Geriatric oncology. 3rd ed. Madrid: Grupo Aula Médica, S.L; 2011. p. 1–18.

    Google Scholar 

  128. Guadagnoli E, Weitberg A, Mor V, et al. The influence of patient age on the diagnosis and treatment of lung and colorectal cancer. Arch Intern Med. 1990;150:1485–90.

    Article  PubMed  CAS  Google Scholar 

  129. Monfardini S, Yancik R. Cancer in the elderly: meeting the challenge of an aging population. J Natl Cancer Inst. 1993;85:532–8.

    Article  PubMed  CAS  Google Scholar 

  130. Satariano WA. Comorbidities and cancer. Cancer in the elderly. In: Hunter CP, Johnson KA, Muss HB, editors. New York: Dekker; 2000. 48: p. 505–12.

    Google Scholar 

  131. Wei JY. Cardiovascular comorbidity in the older cancer patient. Semin Oncol. 1995;22:9–10.

    PubMed  CAS  Google Scholar 

  132. Ginsberg RJ, Hill LD, Eagan RT, et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg. 1983;86:654–8.

    PubMed  CAS  Google Scholar 

  133. Osaki T, Shirakusa T, Kodate M, et al. Surgical treatment of lung cancer in the octogenarian. Ann Thorac Surg. 1994;57:188–92; discussion 192–183.

    Article  PubMed  CAS  Google Scholar 

  134. Thomas P, Sielezneff I, Ragni J, et al. Is lung cancer resection justified in patients aged over 70 years? Eur J Cardiothorac Surg. 1993;7:246–50; discussion 250–241.

    Article  PubMed  CAS  Google Scholar 

  135. Chen J, Jiang R, Garces YI, et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer. 2010;67:221–6.

    Article  PubMed  Google Scholar 

  136. Shepherd FA, Amdemichael E, Evans WK, et al. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc. 1994;42:64–70.

    PubMed  CAS  Google Scholar 

  137. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24.

    Article  PubMed  CAS  Google Scholar 

  138. Schild SE, Stella PJ, Brooks BJ, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer. 2005;103:2349–54.

    Article  PubMed  Google Scholar 

  139. Gridelli C, De Vivo R, Monfardini S. Management of small-cell lung cancer in the elderly. Crit Rev Oncol Hematol. 2002;41:79–88.

    Article  PubMed  CAS  Google Scholar 

  140. Quon H, Shepherd FA, Payne DG, et al. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;43:39–45.

    Article  PubMed  CAS  Google Scholar 

  141. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125:27–37.

    Article  PubMed  Google Scholar 

  142. Batevik R, Grong K, Segadal L, Stangeland L. The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer. 2005;47:173–81.

    Article  PubMed  Google Scholar 

  143. Xie L, Ugnat AM, Morriss J, et al. Histology-related variation in the treatment and survival of patients with lung carcinoma in Canada. Lung Cancer. 2003;42:127–39.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Epidemiology, VieCuri Medical Centre, Tegelseweg 210, Venlo, 5912 BL, The Netherlands

    Maryska L. G. Janssen-Heijnen PhD

Authors
  1. Maryska L. G. Janssen-Heijnen PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maryska L. G. Janssen-Heijnen PhD .

Editor information

Editors and Affiliations

  1. , Department of Oncology/Hematology, S.G. Moscati Hospital, Contrada Amoretta, Avellino, 83100, Italy

    Cesare Gridelli

  2. St Helens Teaching Hospital, University of Liverpool, Marshalls Cross Road, St Helens, WA9 3DA, United Kingdom

    Riccardo A Audisio

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Janssen-Heijnen, M.L.G. (2013). Clinical Epidemiology and the Impact of Comorbidity on Treatment and Outcome. In: Gridelli, C., Audisio, R. (eds) Management of Lung Cancer in Older People. Springer, London. https://doi.org/10.1007/978-0-85729-793-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-793-8_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-792-1

  • Online ISBN: 978-0-85729-793-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation